A carregar...
Publicação
Bristol-myers squibb & celgene: the creation of a global BioPharma leader?
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.25 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
This case is entitled to discuss the strategic motivation of Bristol-Myers Squibb to conduct the merger with the biotechnology company Celgene by considering the company’s current situation as well as the current economic environment. Besides strategic motivations, this case focuses also on the financial merits that may arise in connection with the merger and analyzes the potential impact on shareholder value by taking a closer look at the target company’s business, financial situation as well as expected prospects. As this transaction deviates from Bristol-Myers’ historicallysuccessful M&A strategy and as Celgene is facing an extreme patent cliff on its blockbuster product, shareholders are left questioning the rationale of the deal.
Descrição
Palavras-chave
Mergers & acquisitions Corporate finance Patent cliff